Logo
Please rotate your device

Landscape orientation recommended.

Menu

No results found.

SHC
Sotera Health Company – NASDAQ
Weekly Share Price & Valuation Overview
Market Overview
Open
15.7700
Close
15.7400
High
15.8500
Low
15.6270
Trend
0.28775

Sotera Health Company

United States • NASDAQ - Nasdaq • SHC • Currency: USD

Sotera Health Company provides sterilization, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for the medical device, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

Key strengths
  • Healthy operating margin (≥15%) indicates efficient core operations.
  • High gross margin (≥35%) suggests strong pricing power or cost control.
  • ROA ≥7% shows efficient use of assets.
  • Quick ratio ≥1.0 indicates obligations can be met without inventory.
Potential weaknesses
  • Debt-to-equity >2 — elevated leverage may constrain flexibility.
  • Debt/EBITDA >4 — elevated leverage vs earnings capacity.
Scale & Structure Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.
Market Cap Total equity value of the company (share price × shares outstanding).
USD 4.47B
Enterprise Value Operating value: market cap + total debt − cash.
USD 6.49B
Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
USD 1.12B
Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
USD 624.44M
EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
USD 525.32M
Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
USD 3.97
EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
0.09
Shares Outstanding
284.05M
Float Shares
133.84M
Implied Shares Outstanding
284.05M
Profitability & Efficiency TTM basis. “Reconciled” = numerator ÷ TTM revenue. Margins reflect latest TTM calculations.
Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
35.34%
EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
46.71%
Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
55.53%
Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
2.14%
ROA Strong Return on assets: net income ÷ total assets.
7.24%
ROE Return on equity: net income ÷ shareholder equity.
5.14%
Growth Growth rates are YoY unless labeled QoQ.
Revenue Growth Year-over-year revenue growth.
6.40%
Earnings Growth (YoY) Year-over-year earnings growth.
-6.50%
Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-9.00%
Liquidity & Solvency Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
2.08
Debt to Equity Total debt ÷ shareholder equity; leverage.
4.60
Total Cash Cash and equivalents.
USD 332.63M
Total Debt Short + long-term interest-bearing debt.
USD 2.35B
Net Debt Total debt − cash (negative = net cash).
USD 2.02B
Debt / EBITDA Leverage relative to operating earnings; lower is safer.
4.48
Cash Flow Shown only when internally consistent; margins are TTM.
Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
USD 266.11M
Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
USD 218.81M
OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
23.66%
FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
19.46%
Cash Conversion (OpCF/EBITDA)
0.51
Sharemaestro House View
Confidence: 1 Sharemaestro internal conviction (0–3, higher is better). Risk: 1 Sharemaestro internal risk profile (0–3, higher is safer). Operational: 3 Operational quality/consistency (0–3, higher is better). Composite Score: 2 Overall internal composite (0–3, higher is better). Suggested Allocation: 3.33% Indicative portfolio weighting suggestion based on house view.
Structural Insights (experimental)
Ownership & Liquidity
Free Float Proportion of shares available for public trading. 47.1%
Insiders Shares held by company insiders (officers, directors). 2.5%
Institutions Shares held by institutions (funds, pensions). 96.5%
Capital Structure
Potential Dilution Increase in share count if options/convertibles exercise.
None detected
Net Debt Total debt − cash (negative = net cash).
USD 2.02B
179.6% of revenue Net debt relative to revenue — debt load vs business scale.
Resilience Score 0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating. 34
Methodology Notes
  • Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
  • Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
As of: 2025-08-18 10:09

Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.

AI generated insights not available yet. Sign in to generate the snapshot.